-
Bringing life-changing therapeutics to China and the world.
-
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (EVOMELA®).
September 10, 2019
CASI hosts a key opinion leader (KOL) symposium addressing innovations in cancer immunotherapy. A replay of Nobel Laureate James P. Allison Discussion on Immunotherapy Checkpoint Blockade in Cancer Therapy can be found at https://www.youtube.com/channel/UC5IBDAqhTqt5esL9r3dgQRQ.
August 12, 2019
EVOMELA® received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. It is the only approved and commercially available melphalan product in China.
Press Release
March 16, 2020
Press Release
December 03, 2019
Press Release
November 12, 2019
EVOMELA® (melphalan) for Injection, ZEVALIN® (ibritumomab tiuxetan), and MARQIBO® (vincristine sulfate LIPOSOME injection) are proprietary to Acrotech Biopharma LLC and its affiliates.
© 2020 CASI Pharmaceuticals Inc.
All Rights Reserved.